HC Wainwright Expects Stronger Earnings for Orchestra BioMed

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Orchestra BioMed in a note issued to investors on Monday, March 16th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.33) per share for the quarter, up from their previous forecast of ($0.42). The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Orchestra BioMed’s Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.53) EPS.

Several other research analysts have also recently weighed in on the stock. Barclays boosted their price objective on shares of Orchestra BioMed from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Chardan Capital restated a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a report on Thursday, March 12th. Wall Street Zen raised shares of Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, TD Cowen started coverage on shares of Orchestra BioMed in a research note on Wednesday, December 10th. They set a “buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.25.

Orchestra BioMed Price Performance

OBIO opened at $4.64 on Wednesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 6.43 and a current ratio of 6.45. The stock has a market capitalization of $271.53 million, a P/E ratio of -4.11 and a beta of 0.56. The company’s 50-day simple moving average is $4.19 and its two-hundred day simple moving average is $3.89. Orchestra BioMed has a 52-week low of $2.20 and a 52-week high of $5.42.

Orchestra BioMed (NASDAQ:OBIO) last released its quarterly earnings data on Thursday, March 12th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.38) by $0.64. Orchestra BioMed had a negative return on equity of 184.17% and a negative net margin of 157.40%.The company had revenue of $30.92 million during the quarter, compared to the consensus estimate of $0.93 million.

Institutional Investors Weigh In On Orchestra BioMed

Hedge funds have recently modified their holdings of the business. Bank of America Corp DE increased its stake in shares of Orchestra BioMed by 42.0% in the 4th quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock worth $95,000 after purchasing an additional 7,036 shares in the last quarter. Creative Planning purchased a new position in Orchestra BioMed during the second quarter valued at $40,000. Catalyst Funds Management Pty Ltd purchased a new position in Orchestra BioMed during the second quarter valued at $31,000. XTX Topco Ltd bought a new stake in Orchestra BioMed during the second quarter valued at about $45,000. Finally, Marshall Wace LLP bought a new stake in Orchestra BioMed during the second quarter valued at about $133,000. Institutional investors own 53.20% of the company’s stock.

Insider Transactions at Orchestra BioMed

In other Orchestra BioMed news, insider David P. Hochman bought 10,000 shares of Orchestra BioMed stock in a transaction on Friday, March 13th. The stock was acquired at an average cost of $4.29 per share, with a total value of $42,900.00. Following the completion of the acquisition, the insider owned 1,086,467 shares in the company, valued at approximately $4,660,943.43. This represents a 0.93% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 8.10% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.